Compare Stocks → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ACADNASDAQ:GLPGNASDAQ:HRMYNASDAQ:ROIV Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$16.33-1.6%$20.29$16.16▼$33.99$2.69B0.371.75 million shs585,340 shsGLPGGalapagos$28.58-0.7%$33.51$28.33▼$45.21$1.88B0.24128,335 shs94,648 shsHRMYHarmony Biosciences$28.72-1.7%$31.58$18.61▼$39.26$1.63B0.73371,107 shs111,403 shsROIVRoivant Sciences$10.81-0.8%$10.94$8.06▼$13.24$8.71B1.346.75 million shs1.58 million shs7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals-0.90%-3.49%-7.01%-38.94%-17.50%GLPGGalapagos-2.31%-1.54%-11.96%-23.30%-25.02%HRMYHarmony Biosciences+1.32%+0.14%-10.34%-5.83%-7.97%ROIVRoivant Sciences-0.37%+4.41%+9.55%+3.61%+24.71%Mysterious Gold Leverage Just Announced (Ad)World's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACADACADIA Pharmaceuticals3.57 of 5 stars4.41.00.00.01.04.21.9GLPGGalapagos0.5749 of 5 stars2.02.00.00.02.20.01.3HRMYHarmony Biosciences4.2095 of 5 stars3.30.00.00.03.54.24.4ROIVRoivant Sciences3.4548 of 5 stars4.51.00.00.01.92.51.9Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACADACADIA Pharmaceuticals2.80Moderate Buy$35.82119.37% UpsideGLPGGalapagos2.00Hold$34.5020.71% UpsideHRMYHarmony Biosciences2.50Moderate Buy$40.6341.45% UpsideROIVRoivant Sciences2.90Moderate Buy$16.9056.34% UpsideCurrent Analyst RatingsLatest GLPG, ACAD, HRMY, and ROIV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/22/2024GLPGGalapagosMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingEqual Weight ➝ Equal Weight$38.00 ➝ $38.004/22/2024ROIVRoivant SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.004/12/2024HRMYHarmony BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$49.004/10/2024ACADACADIA PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$37.004/9/2024ACADACADIA PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.004/9/2024HRMYHarmony BiosciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.004/3/2024ROIVRoivant SciencesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$16.00 ➝ $18.004/3/2024ROIVRoivant SciencesDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$14.00 ➝ $15.004/3/2024ROIVRoivant SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$17.00 ➝ $18.003/28/2024GLPGGalapagosBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Underperform$41.00 ➝ $31.003/28/2024HRMYHarmony BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$49.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACADACADIA Pharmaceuticals$726.44M3.70N/AN/A$2.63 per share6.21GLPGGalapagos$259.40M7.26$0.63 per share45.23$45.92 per share0.62HRMYHarmony Biosciences$582.02M2.80$2.60 per share11.06$7.97 per share3.60ROIVRoivant Sciences$61.28M142.15N/AN/A$2.11 per share5.12Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACADACADIA Pharmaceuticals-$61.29M-$0.38N/A13.96N/A-8.44%-15.67%-9.15%5/8/2024 (Confirmed)GLPGGalapagos$229.12M-$2.29N/A476.33N/A-26.25%-2.60%-1.46%5/2/2024 (Estimated)HRMYHarmony Biosciences$128.85M$2.1213.557.290.4022.16%27.49%16.83%4/30/2024 (Confirmed)ROIVRoivant Sciences-$1.01B$5.202.08N/AN/A3,624.14%-33.38%-26.06%6/26/2024 (Estimated)Latest GLPG, ACAD, HRMY, and ROIV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2024N/AACADACADIA Pharmaceuticals$0.17N/A-$0.17N/AN/AN/A4/30/2024N/AHRMYHarmony Biosciences$0.64N/A-$0.64N/AN/AN/A 2/27/2024Q4 2023ACADACADIA Pharmaceuticals$0.32$0.28-$0.04$0.28$223.79 million$231.04 million 2/22/2024Q4 2023HRMYHarmony Biosciences$0.74$0.45-$0.29$0.45$168.90 million$168.40 million 2/13/2024Q3 2024ROIVRoivant Sciences-$0.33-$0.26+$0.07-$6.55$30.72 million$37.14 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACADACADIA PharmaceuticalsN/AN/AN/AN/AN/AGLPGGalapagosN/AN/AN/AN/AN/AHRMYHarmony BiosciencesN/AN/AN/AN/AN/AROIVRoivant SciencesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACADACADIA PharmaceuticalsN/A2.422.28GLPGGalapagosN/A9.028.84HRMYHarmony Biosciences0.382.752.72ROIVRoivant Sciences0.0627.7927.79OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACADACADIA Pharmaceuticals96.71%GLPGGalapagos32.46%HRMYHarmony Biosciences86.23%ROIVRoivant Sciences64.76%Insider OwnershipCompanyInsider OwnershipACADACADIA Pharmaceuticals27.50%GLPGGalapagos2.91%HRMYHarmony Biosciences30.80%ROIVRoivant Sciences4.60%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableACADACADIA Pharmaceuticals597164.77 million119.46 millionOptionableGLPGGalapagos1,12365.90 million63.98 millionOptionableHRMYHarmony Biosciences24656.79 million39.30 millionOptionableROIVRoivant Sciences904805.85 million768.78 millionOptionableGLPG, ACAD, HRMY, and ROIV HeadlinesSourceHeadlineRoivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary Sarcoidosisbusinesswire.com - April 25 at 8:00 AMRoivant Sciences: Cashing In On Vants And Venturesseekingalpha.com - April 24 at 3:15 PMRoivant Sciences (NASDAQ:ROIV) Given "Buy" Rating at HC Wainwrightamericanbankingnews.com - April 23 at 3:26 AMRoivant Sciences (NASDAQ:ROIV) Rating Reiterated by HC Wainwrightmarketbeat.com - April 22 at 8:29 AMSunrun (RUN) Gets a Buy from RBC Capitalmarkets.businessinsider.com - April 14 at 7:09 AMVanguard Group Inc. Has $65.44 Million Position in Roivant Sciences Ltd. (NASDAQ:ROIV)marketbeat.com - April 8 at 4:08 AMResearch Analysts Issue Forecasts for Roivant Sciences Ltd.'s Q1 2025 Earnings (NASDAQ:ROIV)marketbeat.com - April 5 at 8:51 AMRoivant's anti-inflammatory drug shows promise in mid-stage studymsn.com - April 4 at 8:54 AMRoivant Sciences (NASDAQ:ROIV) Sees Large Volume Increase Following Analyst Upgrademarketbeat.com - April 3 at 2:33 PMRoivant Sciences (NASDAQ:ROIV) Given New $18.00 Price Target at The Goldman Sachs Groupmarketbeat.com - April 3 at 12:14 PMRoivant Sciences Ltd. (NASDAQ:ROIV) Given Average Recommendation of "Moderate Buy" by Analystsmarketbeat.com - April 3 at 2:21 AMHealth News Roundup: Abbott's heart valve repair device gains US FDA approval; Gene involved in cell shape offers clues on left-handedness and moredevdiscourse.com - April 2 at 9:50 PMRoivant autoimmune drug succeeds in eye condition; company to buy back $1.5 billion in stockstatnews.com - April 2 at 9:50 PMRoivant Sciences Sees Unusually High Options Volume (NASDAQ:ROIV)marketbeat.com - April 2 at 12:28 PMRoivant Sciences (NASDAQ:ROIV) Shares Gap Up to $10.43marketbeat.com - April 2 at 10:48 AMRoivant Sciences Stock Flirts With Breakout On 'Extremely Positive' Eye-Disease Studymsn.com - April 2 at 9:56 AMRoivant's anti-inflammatory drug succeeds in mid-stage studyreuters.com - April 2 at 7:28 AMRoivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Millionglobenewswire.com - April 2 at 7:00 AMCompare with CoinDesk Market Index (CDICMI)msn.com - April 1 at 1:50 PMAssenagon Asset Management S.A. Has $11.94 Million Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)marketbeat.com - March 29 at 5:16 AMRoivant Sciences (NASDAQ:ROIV) Shares Down 4% marketbeat.com - March 28 at 5:39 PMRoivant Sciences (NASDAQ:ROIV) Shares Gap Up to $10.08marketbeat.com - March 27 at 11:47 AMViking Therapeutics gains on early data for oral weight loss therapymsn.com - March 26 at 8:38 AM'Some people have principles': Internet divided as Vivek Ramaswamy predicts NY ruling against Trump could energize key voter groupmsn.com - March 26 at 8:38 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsACADIA PharmaceuticalsNASDAQ:ACADACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.GalapagosNASDAQ:GLPGGalapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.Harmony BiosciencesNASDAQ:HRMYHarmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.Roivant SciencesNASDAQ:ROIVRoivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.